Anbenitamab (KN026)
HER2-positive breast cancer
Phase 3Active
Key Facts
About AlphaMab Oncology
AlphaMab Oncology develops innovative bispecific antibodies and ADCs for cancer treatment using proprietary glycan-specific conjugation and CRIB platforms.
View full company profileTherapeutic Areas
Other HER2-positive breast cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Membrex™ | Metaclipse Therapeutics | Pre-clinical |
| HER2DX® | Reveal Genomics | Commercial |
| HER2+ cVLP Vaccine | AdaptVac | Phase 1 |
| NERLYNX® (neratinib) | Specialized Therapeutics | Commercial |
| Undisclosed Enhanced Antibody Program | Score Pharma | Pre-clinical |